Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2014 Nov;167(3):418-20.
doi: 10.1111/bjh.12985. Epub 2014 Jun 25.

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012

John T Reilly  1 , Mary Frances McMullin, Philip A Beer, Nauman Butt, Eibhlin Conneally, Andrew S Duncombe, Anthony R Green, George Mikhaeel, Marie H Gilleece, Steven Knapper, Adam J Mead, Ruben A Mesa, Mallika Sekhar, Claire N Harrison
Affiliations
Free article
Practice Guideline

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012

John T Reilly et al. Br J Haematol. 2014 Nov.
Free article
No abstract available

Keywords: CALR; JAK inhibition; myeloproliferative disease.

PubMed Disclaimer

Similar articles

  • Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.
    Tefferi A. Tefferi A. N Engl J Med. 2012 Mar 1;366(9):844-6. doi: 10.1056/NEJMe1115119. N Engl J Med. 2012. PMID: 22375977 No abstract available.
  • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. Verstovsek S, et al. N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557. N Engl J Med. 2012. PMID: 22375971 Free PMC article. Clinical Trial.
  • Ruxolitinib for myelofibrosis.
    Haznedaroglu IC. Haznedaroglu IC. N Engl J Med. 2012 May 24;366(21):2032; author reply 2032-5. doi: 10.1056/NEJMc1203704. N Engl J Med. 2012. PMID: 22621635 No abstract available.
  • Ruxolitinib.
    Becker H, Engelhardt M, von Bubnoff N, Wäsch R. Becker H, et al. Recent Results Cancer Res. 2014;201:249-57. doi: 10.1007/978-3-642-54490-3_16. Recent Results Cancer Res. 2014. PMID: 24756798 Review.
  • Ruxolitinib for the treatment of myelofibrosis.
    Ostojic A, Vrhovac R, Verstovsek S. Ostojic A, et al. Drugs Today (Barc). 2011 Nov;47(11):817-27. doi: 10.1358/dot.2011.47.11.1708829. Drugs Today (Barc). 2011. PMID: 22146225 Review.
See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

LinkOut - more resources